Dirk Blom Articles
Does PCSK9 inhibition have a role in HIV dyslipidaemia?
With HIV (human immunodeficiency virus) patients in developed countries living longer, appropriate management of cardiovascular risk factors, notably dyslipidaemia, becomes more of an issue. But is this also the same in developing regions? As a consequence of developments in HIV management, HIV patients in developed…
read more »
The role of PCSK9 inhibitors in FH
The low density lipoprotein cholesterol (LDL-C) lowering effects of evolocumab, a new PCSK9 inhibitor, in patients with familial hypercholesterolaemia (FH) are very encouraging, Dr Dirk Blom, University of Cape Town says. This will be very important in countries such as South Africa.
read more »
FH issues in low to middle income regions
Despite the availability of statins, treatment of familial hypercholesterolaemia (FH) is a significant issue with a high unmet need in a middle-income country, according to Dr Dirk Blom of Cape Town, South Africa. As a result, new novel therapies are urgently needed.
read more »The role of PCSK9 inhibitors in FH
Monoclonal antibodies targeting PCSK9 have been shown to reduce low density lipoprotein cholesterol (LDL-C) by 30-40% in patients with familial hypercholesterolaemia (FH) who still have LDL receptors. Studies also show that the investigational drug, evolocumab was well tolerated, Dr Dirk Blom said.
read more »
